Bio-Connect
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 microg daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice.
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 microg daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice.
Influence of FLT3L treatment on lymphocyte subpopulations. Method: C57BL/6 mice were injected intraperitoneally with 10 microg daily or were left untreated. (A) Percentages of indicated splenic subpopulations in FLT3L KO, WT control or WT-treated mice.

Fc (human):FLT3 Ligand (human) (rec.)

Research Use Only
AG-40B-0119
AdipoGen Life Sciences
Protein IDP49771
Product group Proteins / Signaling Molecules
Price on request
Packing Size
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Fc (human):FLT3 Ligand (human) (rec.)
  • Delivery Days Customer
    10
  • Certification
    Research Use Only
  • Concentration
    1 mg/ml
  • Estimated Purity
    >95%
  • Protein IDP49771
  • Protein Name
    Fms-related tyrosine kinase 3 ligand
  • Scientific Description
    FMS-like tyrosine kinase 3 ligand (FLT3L) acts as a growth factor that increases the number of immune cells (lymphocytes (B cells and T cells)) by activating the hematopoietic progenitors. It binds to FLT3 (CD135) which is found on multipotent progenitor (MPP) and common lymphoid progenitor (CLP) cells in mice. FLT3L induces the mobilization of the hematopoietic progenitors and stem cells in vivo which may help the system to kill cancer cells. FLT3L is crucial for steady-state pDC (plasmacytoid dendritic cells) and cDC (classical dendritic cells) development. Deficiency of FLT3L causes a dramatic decrease in DC numbers, whereas increasing its availability increase in DC numbers. - Protein. The receptor-binding domain of human FLT3L (aa1-185) is fused at the N-terminus to the Fc portion of human IgG1. Source: CHO cells. Endotoxin content: <0.1EU/microg purified protein (LAL test; Lonza). Liquid. In PBS (sterile). Binds to human and mouse FLT3 receptor. Purity: >95% (SDS-PAGE). FMS-like tyrosine kinase 3 ligand (FLT3L) acts as a growth factor that increases the number of immune cells (lymphocytes (B cells and T cells)) by activating the hematopoietic progenitors. It binds to FLT3 (CD135) which is found on multipotent progenitor (MPP) and common lymphoid progenitor (CLP) cells in mice. FLT3L induces the mobilization of the hematopoietic progenitors and stem cells in vivo which may help the system to kill cancer cells. FLT3L is crucial for steady-state pDC (plasmacytoid dendritic cells) and cDC (classical dendritic cells) development. Deficiency of FLT3L causes a dramatic decrease in DC numbers, whereas increasing its availability increase in DC numbers.
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352202